Reynders McVeigh Capital Management LLC Sells 205 Shares of Zoetis Inc. (NYSE:ZTS)

Reynders McVeigh Capital Management LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,376 shares of the company’s stock after selling 205 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in Zoetis were worth $876,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Callahan Advisors LLC lifted its position in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Pensionfund Sabic lifted its holdings in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new position in Zoetis in the 4th quarter valued at $1,764,000. Finally, Schroder Investment Management Group increased its position in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after buying an additional 6,169 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average target price of $215.90.

Zoetis Stock Performance

Shares of ZTS opened at $149.40 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm’s fifty day simple moving average is $162.51 and its two-hundred day simple moving average is $171.39. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a market capitalization of $66.90 billion, a P/E ratio of 27.31, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.34%. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.